MARKET

DCTH

DCTH

Delcath Sys
NASDAQ
10.67
-0.12
-1.11%
After Hours: 10.68 +0.01 +0.09% 19:32 06/05 EDT
OPEN
10.74
PREV CLOSE
10.79
HIGH
11.21
LOW
10.58
VOLUME
588.21K
TURNOVER
--
52 WEEK HIGH
17.35
52 WEEK LOW
8.12
MARKET CAP
368.35M
P/E (TTM)
1778.33
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at DCTH last week (0525-0529)?
Weekly Report · 06/01 09:16
Delcath Systems announces ASCO 2026 investigator initiated trials-in-progress
TipRanks · 05/26 20:05
Delcath Systems flags Phase 2 study sequencing HEPZATO liver perfusion with tebentafusp in metastatic uveal melanoma
PUBT · 05/26 20:01
H.C. Wainwright Sticks to Its Buy Rating for Delcath Systems (DCTH)
TipRanks · 05/26 17:52
Weekly Report: what happened at DCTH last week (0518-0522)?
Weekly Report · 05/25 09:17
Weekly Report: what happened at DCTH last week (0511-0515)?
Weekly Report · 05/18 09:17
Delcath Systems grants 24,500 RSUs under 2023 inducement plan
PUBT · 05/15 20:01
DELCATH SYSTEMS, INC. ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 05/15 20:01
More
About DCTH
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).

Webull offers Delcath Systems Inc stock information, including NASDAQ: DCTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCTH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DCTH stock methods without spending real money on the virtual paper trading platform.